Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
- Wednesday, June 8, 2022, 7:20
- PR Newswire
- Add a comment
— ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials in China, the U.S. and European Union — Gannex expects to complete this DDI study at the…
About the Author
admin has written 21729 stories on this site.